Press Releases – ADC Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

December 11, 2017

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301

December 11, 2017

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402

November 15, 2017

ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting

October 23, 2017

ADC Therapeutics Announces Closing of $200 Million Private Financing to Fund Two Lead Programs Through Registrational Trials

June 16, 2017

ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma

June 16, 2017

ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML

June 09, 2017

ADC Therapeutics will be attending the 14th International Conference on Malignant Lymphoma June 14-17, 2017 in Lugano, Switzerland

June 09, 2017

ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

May 19, 2017

ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression

March 30, 2017

ADC Therapeutics Presents Pre-Clinical Data for Two Investigational ADCs at the American Association for Cancer Research Annual Meeting